TAIPEI, Jan. 18, 2025 /PRNewswire/ — As a leading brand in PC case innovation, MONTECH introduces the Heritage, a luxurious blend of leather and metal. Featuring a suitcase-style handle, this compact yet spacious PC case redefines portability with elegance and practicality.

Where Luxury Meets Practicality

The Heritage redefines sophistication with its timeless blend of premium leather and durable metal. Signature triangular accents showcase the brand’s identity, while the suitcase-style leather handle combines elegance with portability. Designed for those who value style and functionality, the Heritage offers both striking aesthetics and convenience.

Compact Design, Powerful Performance

Heritage proves that great things come in small packages. Designed to maximize internal capacity and deliver exceptional performance, it supports a wide range of cooling solutions, making it ideal for high-performance build in a compact form factor.

• Top Radiator: 280mm/360mm
• Air Cooler: 170mm
• Fans Support: Up to 9 fans.

With its space-saving design and advanced cooling potential, the Heritage is engineered for users who demand efficiency and power in one elegant package.

Stability Meets Modern Elegance

Breaking away from traditional four-corner designs, the Heritage features sleek, elongated feet that enhance stability and elevate its modern aesthetic, blending functional support with refined style.

Elegance with Practical Utility

The Heritage PRO includes 4 premium GF 120 fans pre-installed and a replaceable handle connection point, enabling users to attach an accessory bracket for hanging headphones or other essentials. This thoughtful feature enhances functionality without compromising the case’s sleek and sophisticated design.

Click here for more information

Release Date & Pricing

The Heritage will be available for purchase on January 18, 2025, 9AM ET.

• Heritage Black & White: US$89.9
• Heritage PRO Black & White: US$109.9 

About MONTECH

Established by Telon Co. Ltd. in 2016, MONTECH is a powerhouse in the PC gaming industry, committed to delivering excellence in every product. With a focus on simplicity in design, unparalleled quality and safety, and user-friendly experiences, MONTECH has earned the trust of PC builders worldwide. Known for providing top-performance products at competitive prices, MONTECH has rapidly ascended to become a market leader in the USA and Asia.

Driven by innovation and a relentless pursuit of perfection, MONTECH is on an aggressive expansion path, bringing its cutting-edge solutions to a global audience. Join the revolution in PC gaming and experience the MONTECH difference.

For more information, visit www.montechpc.com or connect with us on Facebook, Instagram, LinkedIn, YouTube, and X.

HOHHOT, China, Jan. 18, 2025 /PRNewswire/ — Recently, the Yili Elite Summit took place in Hohhot, Inner Mongolia. A total of 400 participants, including 200 employees and their families, gathered at Yili’s headquarters to celebrate this annual event.

During the event, Mr. Pan Gang, Chairman and President of Yili Group, highlighted the crucial role employees play in the company’s success, affirming that the benefits of Yili’s growth should be shared by everyone.

In his address at the opening dinner, Mr. Pan stated, “Family members are the strongest support system for our employees. We appreciate the unwavering support that allows our employees to fully focus on their work and face challenges with resilience. At Yili, we are dedicated to delivering our best at work; we are building a mission centered on health. Our development reflects the career aspirations of our 60,000 employees, the dreams of over 100,000 family members for a better life, the mutual success envisioned by millions of partners within our win-win collaborative ecosystem, and the pursuit of healthy lifestyles by billions of consumers worldwide.” Considering the low temperatures and chilly weather in Hohhot, Mr. Pan also prepared cashmere scarves and gloves for all attendees.

Yili invited employees and their families to tour the Yili Modern Intelligent Health Valley, the corporate headquarters, and the National Center of Technology Innovation for Dairy, providing them with a firsthand look at Yili’s technological advancements and corporate culture. Complementing the tour, Yili organized a series of engaging activities, including health management lectures, a perfume workshop, and DIY cloisonné enamel crafting experience, ensuring a memorable and enriching day for all participants. Guests were also invited to attend the 2024 Annual Meeting and Networking Party, celebrating joyful moments with all Yili members.

The 2025 Yili Elite Summit embodies Yili’s dedication to its people-oriented philosophy and its commitment to creating value for employees. Over the years, Yili has adhered to a talent strategy focused on respect, unity, and bringing success to its employees, fostering mutual progress between the company and all Yili members. The company has upgraded its “Spring Rain Program,” a comprehensive talent well-being initiative, to support employees in housing, healthcare, education and other areas.

Globally, Yili has built an expansive network across Asia, Europe, America, and Oceania. With 15 R&D and innovation centers and 81 production bases, its products are sold in over 60 countries and regions.

Looking forward, Yili remains committed to empowering its employees through innovation, digital intelligence, and employee care programs. By fostering creativity and vitality, Yili aims to drive high-quality, sustainable growth, deliver superior products and services, and realize its vision of “World Integrally Sharing Health”.

HONG KONG, Jan. 18, 2025 /PRNewswire/ — Hong Kong Airlines celebrated the first flight between Hong Kong and Australia’s Gold Coast, marking the airline’s return to become the first local carrier to reinstate this highly anticipated route after several years.

Operating seasonally from 17 January to 15 February 2025, the service covers four flights per week for a four-week period encompassing the Chinese Lunar New Year holiday. The route is operated by an A330 wide-body aircraft, offering both business and economy-class seating.

To commemorate the relaunch, a ceremony was held at the boarding gate before the inaugural flight took off. Hong Kong Airlines President Mr Jeff Sun, representatives of Gold Coast and Queensland Airports, as well as senior representatives of the Airport Authority Hong Kong attended the event, interacted with passengers, and presented bespoke gifts to share the joy.

First flight HX015 to Gold Coast arriving at the Gold Coast Airport at 8:55 am local time. Passengers are welcomed by a lively traditional lion dance performance arranged by the Gold Coast Airport.

Hong Kong Airlines Chairman Mr Yan Bo stated, “We are delighted to have a full flight of passengers on our first voyage, with around 300 travellers coming to experience Queensland’s warm climate and exciting tourist activities. We also look forward to welcoming visitors from the Gold Coast and the Queensland region to Hong Kong during our operation period, inviting them to immerse in the vibrant atmosphere of the Chinese Lunar New Year celebrations and enjoy authentic Hong Kong cuisine.”

Hong Kong Airlines President and Captain Mr Sun joined the cockpit crew to pilot the first flight, he stated, “As one of Hong Kong’s leading full-service airlines, Hong Kong Airlines is committed to providing high-quality, comprehensive services, including flexible baggage allowance options, complimentary inflight meals, and comfortable seats, to ensure that every passenger can enjoy a pleasant journey.”

Queensland Airports Limited CEO Ms Amelia Evans said, “We’re delighted to welcome Hong Kong Airlines’ guests to our beautiful city of Gold Coast and can’t wait for them to experience the best of an Australian summer across the whole region. We hope this connection with Hong Kong will pave the way for longer-term services across our key markets in Hong Kong, the Greater Bay Area, and Mainland China.”

Queensland Tourism Minister Andrew Powell stated, “This influx from Hong Kong over the Lunar New Year period is an exciting opportunity for Gold Coast, supporting local jobs and the economy.”

Tourism and Events Queensland’s (TEQ) Ollie Philpot helped mark the milestone arrival. He commented, “TEQ has worked closely with Hong Kong Airlines and partners including Experience Gold Coast to put the Gold Coast up in lights in Hong Kong and Mainland China to drive demand for these flights and the destination.”

Acting Gold Coast Mayor Donna Gates celebrated the return of this important service after six years and its positive contribution to the region.

Experience Gold Coast CEO John Warn said the resumption of Hong Kong Airlines’ services marks a significant step forward for the Gold Coast’s tourism industry.

“China is a hugely important source market for the Gold Coast, so we are thrilled to see Hong Kong Airlines’ services lift off again,” 

The resumption of the Gold Coast route marks Hong Kong Airlines’ first step back into the long-haul market. The company is progressively expanding its fleet to support a phased expansion of its network, including potential new routes within Australia and a return to the North American market. Additionally, beyond Vancouver, the airline is also actively exploring the possibility of expanding services to Los Angeles, Seattle, and Toronto to offer passengers a wider range of international travel options.

Hong Kong Airlines flight schedule* between Hong Kong and Gold Coast is as follows (All times local): 

For high-resolution photos, please download here: https://bitly.cx/xLwl

About Hong Kong Airlines

Established in 2006, Hong Kong Airlines is a full-service airline firmly rooted in Hong Kong. The airline flies to 30 destinations across the Asia Pacific, and currently maintains interline and codeshares with multiple airline partners and ferry service providers. Hong Kong Airlines operates an all-Airbus fleet. It has been awarded the internationally acclaimed four-star rating from Skytrax since 2011. For more information, please visit hongkongairlines.com or our social media channels on LinkedIn, Twitter, Instagram and Facebook.

MIAMI, Jan. 18, 2025 /PRNewswire/ — The Moskowitz Law Firm, PLLC announces the preliminary approval of a proposed class action settlement that would benefit purchasers and legal title holders of Astrals Non-Fungible Tokens or Galaxy Tokens:

On January 14, 2025, the United States District Court for the Southern District of Florida preliminarily approved a proposed settlement of a class action captioned Harper v. O’Neal, Case No. 23-CV-21912-MORENO. The settlement class includes persons and entities who, from May 24, 2022 to January 14, 2025, purchased Astrals NFTS and/or who, before January 14, 2025, purchased GLXY tokens.

Claims for settlement benefits must be submitted by April 17, 2025. Objections to the settlement and requests for exclusion from the settlement must be received by March 3, 2025 in accordance with the instructions in the Class Notice, which is posted on the settlement website www.astralsnftsettlement.com. The Court will hold a Final Approval Hearing on April 1, 2025, at 9:30 a.m. For more information about the settlement and its terms please visit www.astralsnftsettlement.com.

If you have questions about any matter in this Class Notice, please contact the following representative of Class Counsel, who can answer questions:

Adam M. Moskowitz
The Moskowitz Law Firm, PLLC
P.O. Box 653409
Miami, FL 33175
(305) 740-1423
adam@moskowitz-law.com
service@moskowitz-law.com 

• Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function.
• The transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicity.
• More than 800 million people have Chronic Kidney Disease (CKD), one of the world’s leading causes of mortality worldwide, with associated deaths increasing over the past two decades.¹

ST. LOUIS, Jan. 18, 2025 /PRNewswire/ — MediBeacon Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the MediBeacon^® TGFR for the assessment of kidney function in patients with normal or impaired renal function.

The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace^® (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The system records Lumitrace fluorescence intensity transdermally as a function of time via a sensor placed on the skin. The TGFR Sensor records 2.5 fluorescent readings per second and the TGFR Monitor will display the average session tGFR reading at the patient’s bedside or in the outpatient setting.

The TGFR is validated for use in the assessment of Glomerular Filtration Rate (GFR) in patients with stable kidney function at the point of care. The TGFR utilizes an intravenous Lumitrace injection but does not require blood draws or urine analysis, unlike current methodologies requiring multiple blood draws or urine samples. In addition, current clinical practice measured GFR (mGFR) assessment requires sophisticated clinical laboratory analysis away from the patient’s point of care.

“The development of a system such as the TGFR that assesses a patient’s kidney function without the need to use estimating equations is an important milestone for the nephrology community,” said Dr. Mitchell Rosner, chair of the Department of Medicine at University of Virginia and a highly regarded expert who has authored numerous articles on the challenges of assessing kidney function. “We are excited to explore applications of the transdermal GFR methodology in patients where current clinical practice is understood to be suboptimal.”

Dr. Pierre Galichon, an active kidney researcher at the Sorbonne Université and an attending physician in kidney transplantation at Pitié-Salpêtrière Hospital in Paris, said: “It has long been a challenge to understand kidney function in the context of its interaction with other vital organs, such as the heart and lungs. My experience with MediBeacon products in preclinical use, as relayed in Scientific Reports,² has been exciting, and I look forward to evaluating how transdermal GFR can be applied in clinical practice.”

“The approval of the TGFR by the FDA demonstrates our proprietary system can provide an effective option for assessing kidney function,” said Steve Hanley, CEO of MediBeacon. “According to the National Kidney Foundation, CKD causes more deaths each year than breast cancer or prostate cancer. It is the under-recognized public health crisis.³ The potential applications for the TGFR are numerous, and we look forward to exploring them with clinicians both in the hospital and outpatient settings.”

The timing of FDA approval aligns well with the Q4 2024 publication by MediBeacon’s Chief Scientific Officer, Dr. Richard Dorshow, et al. in Kidney International⁴ with data that supports the utility of MediBeacon’s patented agent Lumitrace^®.

The TGFR met its primary efficacy endpoint as per agreement with the FDA by demonstrating a P30 value of 94% while recruiting patients with a range of GFR values and skin tones. P30 is defined as the percentage of GFR estimation falling within +/- 30% of measured GFR (mGFR) values. 

In clinical studies no serious or severe adverse events have been observed. For more information, including the FDA Summary of Safety and Effectiveness Data, please refer to www.fda.gov.

About MediBeacon Inc.
MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. MediBeacon owns over 55 granted U.S. patents and over 215 granted patents worldwide that provide extensive coverage of the MediBeacon^® TGFR, including Lumitrace^® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR is approved for human use. Potential technology applications in gastroenterology, ophthalmology and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany. For more information, please visit: www.medibeacon.com.

About Lumitrace^® (relmapirazin) injection
Relmapirazin is a non-radioactive, non-iodinated pyrazine-based compound, which has been engineered to be inert, highly fluorescent, and have the clearance properties of a GFR tracer agent in the body. The unique photophysical characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over time and is converted into a transdermal GFR (tGFR) by proprietary algorithms. In a phase 2 investigational study mGFR deduced from Lumitrace matched that of mGFR deduced from iohexol over a range of GFR values. See the peer reviewed article published in the October 2024 issue of Kidney International by Dorshow et al.

IMPORTANT SAFETY INFORMATION FOR TGFR 

Indication for Use:
The MediBeacon^® Transdermal GFR System (TGFR) is intended to assess the Glomerular Filtration Rate (GFR) in adult patients with impaired or normal renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent over time. This device has been validated in patients with stable renal function.

The MediBeacon^® TGFR is not approved for use in patients with GFR <15 ml/min/1.73 m², GFR >120 ml/min/1.73m², patients on dialysis, or anuric patients. The use of this device in patients with dynamic and rapidly changing renal function has not been validated. This device is not intended to diagnose acute kidney injury (AKI).

The MediBeacon^® TGFR Sensor and exogenous tracer agent, Lumitrace^® injection, are single use and are only used with the MediBeacon^® TGFR.

The MediBeacon^® TGFR Sensor is a single use device intended to attach to the patient’s skin and excite fluorescence in Lumitrace^® injection, the tracer agent, and measure the returning light intensity. The data is sent to the MediBeacon^® TGFR Monitor.

Lumitrace^® is an injectable exogenous fluorescent tracer indicated for use with the MediBeacon^® Transdermal GFR System (TGFR) for Glomerular Filtration Rate assessment.

Contraindications:
There are no known contraindications.

Warnings and Precautions:

• See ifu.medibeacon.com for full instructions, warnings, and cautions.
• In clinical studies no serious or severe adverse events have been observed.
• Lumitrace^® injection has light absorbance at 266nm and 435nm, and broad fluorescent emission at ~560nm when excited at ~440nm. Any drug activated at these wavelengths should not be used in conjunction with Lumitrace.
• Lumitrace injection may interfere with clinical laboratory tests. DO NOT ADMINISTER if the patient is expected to need clinical laboratory testing while Lumitrace is present in their system (up to 72 hours for renally-impaired patients). The presence of Lumitrace decreased B-Type Natriuretic Peptide (BNP) results by around 20% in limited testing.
• Bolus infusions may impact the GFR assessment temporarily while the vasculature-tissue equilibrium is re-established.
• During a TGFR session, the patient should be as still as possible, especially during the “Establishing Baseline” stage. The current system is designed to compensate for light activity such as reading or eating after the Baseline stage.

¹ Epidemiology of chronic kidney disease: an update 2022, Kidney International Supplement, 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003., Csaba P Kovesdy
² Pulmonary hypertension without heart failure causes cardiorenal syndrome in a porcine model, Scientific Reports (2023) 13:9130, Orieux et al, doi.org/10.1038/s41598-023-36124-1
³ National Kidney Foundation, Fast Facts (2024 Update), Updated as of 8/6/2024
⁴ Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102), Kidney International, Volume 106, Issue 4, P679-687, October 2024, DOI: 10.1016/j.kint.2024.06.012